On the in vivo significance of bacterial resistance to antimicrobial peptides.
On the in vivo significance of bacterial resistance to antimicrobial peptides.
复制标题
DOI：
10.1016/j.bbamem.2015.02.012
复制
发表时间：
2015-11
期刊：
影响因子：
--
通讯作者：
Shafer WM
中科院分区：
文献类型：
--
作者：
Bauer ME;Shafer WM
抗菌肽 (AMP) 处于感染期间宿主防御的前线，在减少感染早期微生物负荷以及将先天性免疫与适应性免疫联系起来方面发挥着关键作用。然而，成功的病原体已经开发出抵抗 AMP 的机制。尽管在阐明体外致病菌的 AMP 抗性机制方面已经取得了相当大的进展，但对于这种抗性的体内意义却知之甚少。尽管如此，这一领域已经取得了进展，主要是通过使用小鼠模型，以及在两个例子中使用人类感染模型。在此，我们回顾了在 AMP 研究中使用体内感染模型的进展，并讨论了体内研究已建立的导致微生物感染的 AMP 耐药机制。我们认为体内感染模型是研究人员了解影响细菌对 AMP 敏感性水平的遗传变化对发病机制的重要性的重要工具。
Antimicrobial peptides (AMPs) are at the front-line of host defense during infection and play critical roles both in reducing the microbial load early during infection and in linking innate to adaptive immunity. However, successful pathogens have developed mechanisms to resist AMPs. Although considerable progress has been made in elucidating AMP-resistance mechanisms of pathogenic bacteria in vitro, less is known regarding the in vivo significance of such resistance. Nevertheless, progress has been made in this area, largely by using murine models and, in two instances, human models of infection. Herein, we review progress on the use of in vivo infection models in AMP research and discuss the AMP resistance mechanisms that have been established by in vivo studies to contribute to microbial infection. We posit that in vivo infection models are essential tools for investigators to understand the significance to pathogenesis of genetic changes that impact levels of bacterial susceptibility to AMPs.